Literature DB >> 34129913

The HECT family of E3 ubiquitin ligases and PTEN.

Min Sup Song1, Pier Paolo Pandolfi2.   

Abstract

Members of the HECT family of E3 ubiquitin ligases have emerged as prominent regulators of PTEN function, subcellular localization and levels. In turn this unfolding regulatory network is allowing for the identification of genes directly involved in both tumorigenesis at large and cancer susceptibility syndromes. While the complexity of this regulatory network is still being unraveled, these new findings are paving the way for novel therapeutic modalities for cancer prevention and therapy as well as for other diseases. Here we will review the signal transduction and therapeutic implications of the cross-talk between HECT family members and PTEN.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HECT family of E3 ubiquitin ligase; I3C; NEDD4; PTEN; WWP1

Year:  2021        PMID: 34129913      PMCID: PMC8665946          DOI: 10.1016/j.semcancer.2021.06.012

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  102 in total

Review 1.  The Nedd4-like family of E3 ubiquitin ligases and cancer.

Authors:  Ceshi Chen; Lydia E Matesic
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

2.  Control of the activity of WW-HECT domain E3 ubiquitin ligases by NDFIP proteins.

Authors:  Thomas Mund; Hugh R B Pelham
Journal:  EMBO Rep       Date:  2009-04-03       Impact factor: 8.807

Review 3.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

4.  The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate.

Authors:  T Maehama; J E Dixon
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

5.  A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.

Authors:  Min-Han Tan; Jessica Mester; Charissa Peterson; Yiran Yang; Jin-Lian Chen; Lisa A Rybicki; Kresimira Milas; Holly Pederson; Berna Remzi; Mohammed S Orloff; Charis Eng
Journal:  Am J Hum Genet       Date:  2010-12-30       Impact factor: 11.025

6.  The Angelman syndrome candidate gene, UBE3A/E6-AP, is imprinted in brain.

Authors:  C Rougeulle; H Glatt; M Lalande
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

7.  Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta.

Authors:  Anna Maria Al-Khouri; Yuliang Ma; Summanuna H Togo; Scott Williams; Tomas Mustelin
Journal:  J Biol Chem       Date:  2005-08-17       Impact factor: 5.157

8.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

9.  Impeded Nedd4-1-mediated Ras degradation underlies Ras-driven tumorigenesis.

Authors:  Taoling Zeng; Qun Wang; Jieying Fu; Qi Lin; Jing Bi; Weichao Ding; Yikai Qiao; Sheng Zhang; Wenxiu Zhao; Huayue Lin; Meilin Wang; Binfeng Lu; Xianming Deng; Dawang Zhou; Zhenyu Yin; Hong-Rui Wang
Journal:  Cell Rep       Date:  2014-04-17       Impact factor: 9.423

10.  Crucial role of the C-terminus of PTEN in antagonizing NEDD4-1-mediated PTEN ubiquitination and degradation.

Authors:  Xinjiang Wang; Yuji Shi; Junru Wang; Guochang Huang; Xuejun Jiang
Journal:  Biochem J       Date:  2008-09-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.